HIZENTRA: The appearance is out of specification in the affected lot.
Brand(s)
Last updated
Summary
Product
HIZENTRA
Issue
Health products - Product safety
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| Hizentra | Hizentra | DIN 02463067 | Solution | Subcutaneous Immunoglobulin (Human) 20% Solution for injection (2g/10mL) | P100834477 |
Issue
The appearance is out of specification in the affected lot.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: End users
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
CSL Behring Canada, Inc.
55 Metcalfe Street, Suite 350,
Ottawa, ON
K1P 6L5
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Recall date
Identification number
RA-81796
Get notified
Receive emails about new and updated recall and safety alerts.